Publications by authors named "I Toledano"

Claim this Profile
D
Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study.
A R Filippi, M R García Campelo, J-B Paoli, D Kowalski, C Bennati, I Toledano

ESMO Open· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genome-scale quantification and prediction of pathogenic stop codon readthrough by small molecules.
Ignasi Toledano, Fran Supek, Ben Lehner

Nat Genet· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SUNi mutagenesis: Scalable and uniform nicking for efficient generation of variant libraries.
Taylor L Mighell, Ignasi Toledano, Ben Lehner

PLoS One· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models.
Marc Masanas, Nuria Masiá, Leticia Suárez-Cabrera, Mireia Olivan, Aroa Soriano, Ignasi Toledano

Clin Transl Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
H S Rugo, F André, T Yamashita, H Cerda, I Toledano

Ann Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis